BIOMAT Database Logo BIOMAT Database Logo

Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. 1995

J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Department of Clinical Pharmacology, Sandoz Pharma Ltd., Basel, Switzerland.

Potential differences in the acute effect of cyclosporin on renal function when dosed orally as the current market formulation or following a milligram-to-milligram conversion to a new microemulsion formulation were investigated in 14 stable kidney transplant patients. The study consisted of three sequential periods of 2 weeks duration each. Patients entered (period I) and completed (period III) the investigation with the market formulation and received the microemulsion formulation in period II; individualized cyclosporin doses remained unchanged throughout the study. Over one steady-state dosing interval at the end of each study period, whole blood cyclosporin pharmacokinetic profiles were assessed in parallel with endogenous creatinine clearances over sequential 1- to 2-h intervals. The rate and extent of cyclosporin absorption were significantly greater (P < 0.01) from the microemulsion formulation with average increases of 73% in peak concentration and 44% in area under the curve compared to the market formulation. Sequential creatinine clearances exhibited a transient decrease with the nadir occurring on average between 4 and 6 h post dose followed by a rapid return to baseline. Specifically in period I on the market formulation, clearances decreased from a baseline of 71.7 +/- 20.6 to a minimum of 51.1 +/- 17.9 ml/min per 1.73 m2 (similar values in period III) and from 76.8 +/- 24.8 to 53.5 +/- 17.5 ml/min 1.73 m2 in period II on the microemulsion. Neither the baseline nor minimum clearances were significantly different among the study periods.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
[Safety in the switching traditional cyclosporin to microemulsion cyclosporin in stable renal transplant patients: cooperative study].
December 1995, Investigacion clinica,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.
August 1998, Transplantation proceedings,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
October 1998, Clinical transplantation,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Cyclosporine conversion from conventional to microemulsion formulation: effect on renal concentration ability in stable hepatic transplant recipients.
January 1997, Transplantation proceedings,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Microemulsion cyclosporin formulation, in contrast to the old formulation, widens the T lymphocyte subsets differences between stable and acute rejection of kidney transplants.
June 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year.
January 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Cyclosporin absorption from microemulsion formulation in liver transplant recipient.
February 1993, Lancet (London, England),
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin.
December 2003, British journal of clinical pharmacology,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
November 1998, Transplantation proceedings,
J M Kovarik, and Z Kallay, and E A Mueller, and J B van Bree, and W Arns, and E Renner
Influence of bile on cyclosporin absorption from microemulsion formulation in primary liver transplant recipients.
January 1995, Transplant international : official journal of the European Society for Organ Transplantation,
Copied contents to your clipboard!